Neisseria 1 0 1 1 0 1 Pseudomonal 1 1 2 1 1 2 Staphylococcal 1 0 1 1 0 1 Streptococcal 1 0 1 1 0 1 Fungal 0 0 0 0 1 1 Pneumocystis 0 0 0 0 1 1 Infections—pathogen unspecified* 16 7 23 34 12 46 Viral 0 1 1 1 1 2 Hepatitis 0 1 1 0 1 1 Influenza 0 0 0 1 0 1 Total 21 9 30 40 15 55 MPT, melphalan, prednisone, and thalidomide; Rd cont, lenalidomide plus low-dose dexamethasone until disease progression; Rd18, lenalidomide plus low-dose dexamethasone for 18 cycles; TE, treatment emergent. * In total, 30 of these infections were reported as sepsis, bacteremia, viremia, and fungemia other; 13 as lower respiratory tract and lung infections; 2 as central nervous system and spinal infections; and 1 as other infections.
Neisseria Pseudomonal Staphylococcal Streptococcal 1 1 1 1 0 1 0 0 1 2 1 1 1 1 1 1 0 1 0 0 1 2 1 1 Fungal Pneumocystis 0 0 0 0 0 0 0 0 1 1 1 1 Infections—pathogen unspecified* 16 7 23 34 12 46 Viral Hepatitis Influenza 0 0 0 1 1 0 1 1 0 1 0 1 1 1 0 2 1 1 Total 21 9 30 40 15 55 MPT, melphalan, prednisone, and thalidomide; Rd cont, lenalidomide plus low-dose dexamethasone until disease progression; Rd18, lenalidomide plus low-dose dexamethasone for 18 cycles; TE, treatment emergent. * In total, 30 of these infections were reported as sepsis, bacteremia, viremia, and fungemia other; 13 as lower respiratory tract and lung infections; 2 as central nervous system and spinal infections; and 1 as other infections.
41375_2018_133_MOESM1_ESM.docx